Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: L01 - Antineoplastic agents
Drug: L01X - Other antineoplastic agents
Drug: L01XE - Protein kinase inhibitors
Drug: L01XE31 - Nintedanib
Drug: L - Antineoplastic and immunomodulating agents

First Posted Date: 2017-09-13

Last Posted Date: 2019-08-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 172

Registration Number: NCT03281200

Locations: 🇪🇸
Dynamic solutions, Barcelona, Spain

This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357

Phase 1

Completed

Conditions: Psoriasis
Healthy

Interventions: Drug: Placebo
Drug: BI 730357
Drug: Midazolam

First Posted Date: 2017-09-12

Last Posted Date: 2024-12-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 83

Registration Number: NCT03279978

Locations: 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: ICS (Inhaled Corticosteroid) (Triple therapy)
Drug: Stiolto Respimat
Drug: LABA (Long-Acting Beta Agonist) (Triple therapy)
Drug: LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)

First Posted Date: 2017-08-29

Last Posted Date: 2022-06-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 714

Registration Number: NCT03265145

Locations: 🇺🇸
Aureus Medical Group, Inc, Rancho Cucamonga, California, United States
🇺🇸
HealthCare Partners, Commerce, California, United States
🇺🇸
Advanced Research for Health Improvement, LLC, Naples, Florida, United States

and more 83 locations

This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran

First Posted Date: 2017-08-23

Last Posted Date: 2020-07-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1489

Registration Number: NCT03258645

Locations: 🇸🇪
SITS International (c/o Karolinska University Hospital), Stockholm, Sweden

This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 685509

First Posted Date: 2017-08-23

Last Posted Date: 2018-07-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT03259464

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin/linagliptin/metformin HCl
Drug: Empagliflozin
Drug: Linagliptin
Drug: Metformin HCl

First Posted Date: 2017-08-23

Last Posted Date: 2020-03-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT03259490

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Medical Need of OAC Reversal

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: warfarin
Drug: dabigatran
Drug: Apixaban
Drug: Edoxaban
Drug: Rivaroxaban

First Posted Date: 2017-08-18

Last Posted Date: 2019-03-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53969

Registration Number: NCT03254147

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Warfarin
Drug: Dabigatran

First Posted Date: 2017-08-18

Last Posted Date: 2019-07-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22490

Registration Number: NCT03254134

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan

Completed

Conditions: Pulmonary Fibrosis

Interventions: Drug: nintedanib
Drug: pirfenidone

First Posted Date: 2017-08-08

Last Posted Date: 2021-04-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 101

Registration Number: NCT03242759

Locations: 🇨🇳
Chang-Hua Christian Hospital, Changhua, Taiwan
🇨🇳
Chang Gung Memorial Hospital(Linkou), Tao-Yuan, Taiwan
🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan

and more 7 locations

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Fluticasone propionate
Drug: Tiotropium
Drug: Salmeterol
Drug: Olodaterol

First Posted Date: 2017-08-07

Last Posted Date: 2020-04-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 302

Registration Number: NCT03240575

Locations: 🇺🇸
Pulmonary Rsrch Inst of SE MI, Farmington Hills, Michigan, United States
🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 39 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy